Checkmate 77T: Perioperative chemoimmunotherapy outperforms in early-stage NSCLC

被引：0

作者：

Brazel, Danielle ^{[1
]}

Nagasaka, Misako ^{[2
,3
]}

机构：

[1] Scripps Green Hosp, Scripps Clin, Dept Hematol Oncol, 10166 N Torrey Pines Rd, La Jolla, CA 92037 USA

[2] Univ Calif Orange, Chao Family Canc Ctr, Irvine Sch Med, 101 City Dr, Orange, CA 92868 USA

[3] St Marianna Univ, Sch Med, Kawasaki, Japan

来源：

MED | 2024年 / 5卷 / 08期

关键词：

D O I：

10.1016/j.medj.2024.06.012

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Approximately 1 in 4 patients with NSCLC present with resectable disease. Although surgery is potentially curative, 30%-50% of patients relapse. Studies have shown that neoadjuvant, adjuvant, and perioperative chemoimmunotherapy improve outcomes. The Checkmate 77T trial explored if perioperative platinum-based chemotherapy plus nivolumab, surgical resection, then adjuvant nivolumab further improved outcomes including EFS.

引用

页码：852 / 855

页数：4

共 50 条

[21] CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage IIeIIIb NSCLC
Cascone, T.
Awad, M. M.
Spicer, J. D.
He, J.
Lu, S.
Sepesi, B.
Tanaka, F.
Taube, J. M.
Cornelissen, R.
Havel, L.
Kuzdzal, J.
Petruzelka, L. B.
Wu, L.
Pujol, J. L.
Ito, H.
Erdmann, C. Coronado
Sathyanarayana, P.
Meadows-Shropshire, S.
Pulla, M. Provencio
ANNALS OF ONCOLOGY, 2023, 34 : S1295 - S1295
[22] Perioperative Targeted Therapy for Operable, Early Stage NSCLC
Etman, Samer
Saalfeld, Felix
Aust, Daniela
Sombati, Monika
Decker, Rahel
Schweipert, Johannes
Baum, Daniel
Wermke, Martin
Ploenes, Till
ZENTRALBLATT FUR CHIRURGIE, 2024, 149 : S45 - S51
[23] Early-stage NSCLC: promising (neo)adjuvant approaches
不详
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2019, 12 : E46 - E49
[24] Early-Stage NSCLC: Advances in Thoracic Oncology 2018
Osarogiagbon, Raymond U.
Veronesi, Giulia
Fang, Wentao
Ekman, Simon
Suda, Kenichi
Aerts, Joachim G.
Donington, Jessica
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (06) : 968 - 978
[25] VATS and Minimally Invasive Resection in Early-Stage NSCLC
Salfity, Hai
Tong, Betty C.
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 41 (03) : 335 - 345
[26] Is There Clinical Value to Prognostic Signatures in Early-Stage NSCLC?
Bunn, Paul A., Jr.
Hirsch, Fred R.
Aisner, Dara L.
CLINICAL CANCER RESEARCH, 2014, 20 (07) : 1727 - 1729
[27] Current status of immune checkpoint inhibition in early-stage NSCLC
Vansteenkiste, J.
Wauters, E.
Reymen, B.
Ackermann, C. J.
Peters, S.
De Ruysscher, D.
ANNALS OF ONCOLOGY, 2019, 30 (08) : 1244 - 1253
[28] Prognosticator of SBRT efficacy and toxicity in early-stage NSCLC patients
Walz, D.
Salome, P.
Sforazzini, F.
Kudak, A.
Dostal, M.
Regnery, S.
Schlamp, K.
Heussel, C. P.
Herth, F.
Thomas, M.
Hoerner-Rieber, J.
Debus, J.
Knoll, M.
Abdollahi, A.
RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S1070 - S1071
[29] Sequence of Vessel Interruption in VATs Lobectomy for Early-Stage NSCLC
Li, Yun
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S769 - S769
[30] ILK STATUS AND THE PROGRESSION OF EARLY-STAGE NSCLC: A PILOT STUDY
Watzka, S. B.
Poetsch, I.
Marcher, M.
Setinek, U.
Weigel, G.
Mueller, M. R.
LUNG CANCER, 2009, 64 : S47 - S47

← 1 2 3 4 5 →